Psoriatic arthritis

      To #cycle within or go to another drug class I #axSpA?

      #RCT of #TNFi-IR
      👇
      2nd #TNFi v #IL17i

      #IJDM it doesn’t ma

      Janet Pope Janetbirdope

      3 months ago
      To #cycle within or go to another drug class I #axSpA? #RCT of #TNFi-IR 👇 2nd #TNFi v #IL17i #IJDM it doesn’t matter what choice as #IL17i WAS NOT superior to TNFi cycling from 1st -2nd 👍 stay in #TNFi class = change to #IL17i #ACR25 @RheumNow abst#LB09 #ACRBest @ACRheum https://t.co/VCdL5CUYUa
      The CLASSIC study validated the performance of the 2009 ASAS classification criteria

      Model A was chosen for the revised

      sheila RHEUMarampa

      3 months ago
      The CLASSIC study validated the performance of the 2009 ASAS classification criteria Model A was chosen for the revised criteria since it achieved prespecified performance targets of SN ≥75% and SP ≥90% 🔸Pso was included 🔸⬆️CRP replaced dactylitis #ACR25 @RheumNow Abs0854 https://t.co/tK52rQyaRa
      In a global retrospective study of 90,536 PsA patients, those on GLP-1 receptor agonists (n=4,104) had significantly low

      Antoni Chan MD (Prof) synovialjoints

      3 months ago
      In a global retrospective study of 90,536 PsA patients, those on GLP-1 receptor agonists (n=4,104) had significantly lower risk of major cardiovascular events and reduced mortality vs non-users. Most common GLP-1 RA: semaglutide. Supports future research on cardiometabolic https://t.co/ccOL10gD5b
      Time for the 2nd plenary session! 🎤
      #0849 GLP-1 receptor agonists in #PsA linked with lower mortality & fewer maj

      Mrinalini Dey DrMiniDey

      3 months ago
      Time for the 2nd plenary session! 🎤 #0849 GLP-1 receptor agonists in #PsA linked with lower mortality & fewer major cardiac events in >90K patients. Promising data for inflammation, weight & heart health in PsA care. @RheumNow #ACR25 https://t.co/8zyrSrumOP
      This morning in the plenary, same theme, but in PsA:
      Similar metabolic/CV concerns
      Similarly benefit from GLP-1 RA

      look

      David Liew drdavidliew

      3 months ago
      This morning in the plenary, same theme, but in PsA: Similar metabolic/CV concerns Similarly benefit from GLP-1 RA looking at TriNetX data again, reduced MACE Now prospective trials in rheum disease, for both metabolic benefits & disease activity? #ACR25 ABST0849 @RheumNow https://t.co/DHZN1hwbIG
      GLP-1.pink
      GLP-1 Receptor Agonists: Impacts Beyond Metabolism?
      3 months ago
      The GLP-1 story has been hard to miss this year, and at ACR Convergence, it’s clear that these drugs are starting to make real waves in rheumatology. Across multiple abstracts, investigators have used a large real-world dataset, the TriNetX network, to explore how GLP-1 receptor agonists (GLP-1RAs) might influence cardiovascular, renal and immune-mediated outcomes in our patients.
      Increased risk of psoriatic arthritis with obesity. A preview to Abstract#2687 Scher J @RheumNow #ACR25 https://t.co/cMb

      Antoni Chan MD (Prof) synovialjoints

      3 months ago
      Increased risk of psoriatic arthritis with obesity. A preview to Abstract#2687 Scher J @RheumNow #ACR25 https://t.co/cMbrQnq8YG
      Psoriatic Arthritis Imaging
      3 months ago
      High prevalence of sleep related symptoms in PsA pts!
      -Snoring 53%
      -Morning fatigue 68%
      -Obstructive Sleep Apnea in

      Aurelie Najm AurelieRheumo

      3 months ago
      High prevalence of sleep related symptoms in PsA pts! -Snoring 53% -Morning fatigue 68% -Obstructive Sleep Apnea in 50% 14% mild 19% moderate 17% severe Estimated prevalence 36% No correlation between OSA and PsA disease activity or comorbidities But small cohort! https://t.co/VKe7qcHIRm
      Dr. Ogdie on emerging PsA tx:
      “It’s not just about the pharmacotherapy but also about making the patient feel bette

      sheila RHEUMarampa

      3 months ago
      Dr. Ogdie on emerging PsA tx: “It’s not just about the pharmacotherapy but also about making the patient feel better” Also, weight loss is incredibly important but also incredibly hard. Losing weight is more impt than the type of diet a patient should be on. #ACR25 @RheumNow https://t.co/FN3EEowkDP
      Why do we need to identify early PsA?
      🔅Improve symptoms
      🔅Prevent radiographic progression
      🔅Preserve function

      ?

      sheila RHEUMarampa

      3 months ago
      Why do we need to identify early PsA? 🔅Improve symptoms 🔅Prevent radiographic progression 🔅Preserve function ☝️Recent data show that erosions are prevalent in early PsA but lower if symptom duration is <6 mos. #ACR25 @RheumNow https://t.co/sEGXzd8RiD
      What are the RFs for progression of Pso to PsA?
      🔸PsO disease severity - 3.2x risk —>PsA
      🔸Phenotype - nail in

      sheila RHEUMarampa

      3 months ago
      What are the RFs for progression of Pso to PsA? 🔸PsO disease severity - 3.2x risk —>PsA 🔸Phenotype - nail involvement 🔸Obesity - 6x higher risk of developing PsA 🔸MSK symptoms - arthralgia & heel pain #ACR25 @RheumNow https://t.co/UPXuxBPyKI
      The severity of skin psoriasis increases the risk of psoriatic arthritis. Scher J @RheumNow #ACR25 https://t.co/EI0ACWAC

      Antoni Chan MD (Prof) synovialjoints

      3 months ago
      The severity of skin psoriasis increases the risk of psoriatic arthritis. Scher J @RheumNow #ACR25 https://t.co/EI0ACWACHy
      Trying to reach RA, PsA patients on social media, to participate in studies?

      Simple, informational messages work for re

      David Liew drdavidliew

      3 months ago
      Trying to reach RA, PsA patients on social media, to participate in studies? Simple, informational messages work for recruitment Message framing affects engagement but not recruitment The more we understand, the better we can reach the right people #ACR25 ABST0187 @RheumNow https://t.co/JoAthXhXvi
      A simple flow cytometry analysis of peripheral blood monocytes to predicts progression to clinical RA or PsA in at-risk

      Aurelie Najm AurelieRheumo

      3 months ago
      A simple flow cytometry analysis of peripheral blood monocytes to predicts progression to clinical RA or PsA in at-risk patients? Too good to be true! 284 RA 56 PsA 57 HC -HLA-DR higher in PsA -CD11c lower in RA But no clear difference between Converters and non Converters https://t.co/f3Sett4eXd

      Podcasts

      • ACR 2025 PsA Topic Podcasts Compilation 6
      • ACR 2025 Daily Podcasts Day4b
      • ACR 2025 Daily Podcasts Day4a

      Catch up on Conference Podcasts

      ×